Case Reports in Rheumatology / 2016 / Article / Tab 1

Case Report

A Case of Dermatomyositis and Anti-EJ Autoantibody with Chronic Intestinal Pseudoobstruction Successfully Treated with Octreotide

Table 1

Characteristics of CIPO complicated with connective tissue disease treated with octreotide.

DiagnosisSex/ageOctreotide (dosage, routes of administration)EffectSclerodermaRaynaud’s phenomenonDiminished esophageal peristalsisILDDiarrheaConstipationAntibodies and other features

Soudah et al. 1991SScM/6350 μg, SC+++n.a.+++Myopathy
SScF/6550 μg, SC++n.a.++
SScF/6050 μg, SC+++n.a.++
SScM/5750 μg, SC++n.a.++
SScM/5550 μg, SC+++n.a.++

Kobayashi et al. 1993SScF/2650 μg, SC+++n.a.n.a.+

Lanting et al. 1993SSc/PMF/5150 μg, SC++n.a.+++

Yamamoto et al. 1994SScF/29100 μg, SC++n.a.n.a.+++α-RNP, myopathy

Ono et al. 1996SScF/28100 μg, SC+++n.a.++
SScF/47100 μg, SC+++n.a.+

Kanbe et al. 1996SScF/61100 μg, SC+++n.a.++

Ishikawa et al. 1999SScF/66SC+++++++
SSc/PMF/35SC+++++α-RNP, Ku

Perlemuter et al. 1999SSF/19100 μg, SC+n.a.n.a.+α-RNP, SSA
SLEF/52100–400 μg, SC+n.a.n.a.++α-RNP, DNA
SScF/7050–100 μg, SC++++n.a.+α-Scl-70, Jo-1, PM-1

Descamps et al. 1999SSc/PMF/5375 μg, SC+++n.a.n.a.+Dysphagia

Matsuki et al. 2000SScM/6450 μg, SC+++n.a.++
SScF/65100 μg, SC+++++α-Scl-70

Marie et al. 2001PMM/5550 μg, SC++

Malcolm and Ellard 2001SScF/7550 μg, SC++++Intestinal perforation

Suzuki et al. 2005SSc/PMF/31100 μg, SC++++α-Ku

Leonardi et al. 2010SLEF/5150 μg, SCn.a.+n.a.+PSL pulse was effective

Our case 2016DMF/38100 μg IV, 50 μg SC, 30 mg IM+++++α-RNP, SSA, EJ

Dosage was not available, partial response.
ILD: interstitial lung disease; SSc: systemic sclerosis; SS: Sjögren’s syndrome; PM: polymyositis; DM: dermatomyositis; SLE: systemic lupus erythematosus; n.a.: not available.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.